ACE and diabetes mellitus: However, our study allows a cautious optimism regarding adequate cardiac protection of RAS-inhibition in patients with diabetes, suggesting that achievement of tight glycemic control normalizes the anti-remodeling effects of ACE-I and ARB therapy.